Antiviral efficacy of entecavir in nucleos(t)ide-naïve patients of Black/African descent with chronic hepatitis B

2013 ◽  
Vol 21 (1) ◽  
pp. 74-76 ◽  
Author(s):  
L. Jeffers ◽  
C. J. Van Rensburg ◽  
A. Banks ◽  
M. Schechter ◽  
S. J. Schmidt ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
African Descent ◽  
Black African ◽  
Antiviral Efficacy

scholarly journals Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B

2017 ◽  
Vol 186 (3) ◽  
pp. 356-366 ◽  
Author(s):  
Mohamed A. Hassan ◽  
W. Ray Kim ◽  
Ruosha Li ◽  
Coleman I. Smith ◽  
Michael W. Fried ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
African Descent ◽  
Foreign Born

scholarly journals Treatment with the Immunomodulator AIC649 in Combination with Entecavir Produces Antiviral Efficacy in the Woodchuck Model of Chronic Hepatitis B

Viruses ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 648
Author(s):  
Kyle E. Korolowicz ◽  
Manasa Suresh ◽  
Bin Li ◽  
Xu Huang ◽  
Changsuek Yon ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Combination Treatment ◽  
Response Pattern ◽  
Biphasic Response ◽  
Viral Control ◽  
Short Term Treatment ◽  
Viral Dna ◽  
Antiviral Efficacy

As current interventions for chronic hepatitis B (CHB) rarely induce cure, more effective drugs are needed. Short-term treatment of woodchucks with the novel immunomodulator AIC649, a parapoxvirus-based stimulator of toll-like receptor 9 dependent and independent pathways, has been shown to reduce viral DNA and surface antigen via a unique, biphasic response pattern. The present study evaluated long-term AIC649 treatment in combination with Entecavir for potency and safety in woodchucks. AIC649 monotreatment induced modest reductions in serum viral DNA and surface and e antigens that were associated with the same biphasic response pattern previously observed. Entecavir monotreatment reduced transiently viremia but not antigenemia, while AIC649/Entecavir combination treatment mediated superior viral control. Undetectability of viral antigens and elicitation of antibodies in AIC649/Entecavir-treated woodchucks correlated with the expression of interferons and suppression of viral replication in liver. Combination treatment was well tolerated, and liver enzyme elevations were minor and transient. It was concluded that the AIC649-mediated effects were most likely based on an improvement and/or reconstitution of antiviral immune responses that are typically deficient in CHB. As a combination partner to Entecavir, the antiviral efficacy of AIC649 was markedly enhanced. This preclinical study supports future evaluation of AIC649 for treatment of human CHB.

scholarly journals Virologic Response at 12 Months of Treatment Predicts Sustained Antiviral Efficacy in Patients with Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B

Gut and Liver ◽  
2010 ◽  
Vol 4 (2) ◽  
pp. 212-218 ◽  
Author(s):  
Young Kul Jung ◽  
Jong Eun Yeon ◽  
Woo Sik Han ◽  
Ji Hoon Kim ◽  
Jeong Han Kim ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Virologic Response ◽  
Antiviral Efficacy
Sign in / Sign up

Export Citation Format

Share Document